- Developed by Oxford University and AstraZeneca (British-Swedish multinational pharmaceutical and biopharmaceutical company).
- It’s one of the first vaccines that entered into human trials in July.
- Currently under phase 3 final trials in US and "very close to the end" as announced by Donald Trump.
- The Serum Institute of India (SII) is also conducting Oxford’s vaccine Phase 2 and 3 trials in India.
- SII is also producing over 2 crore (200 million) doses of the Oxford's coronavirus vaccine.
- It’s touted to be the first vaccines that may be available for civilian use.
- The vaccine will be called Covishield in India, as informed by SII CEO Adar Poonawalla.
- Over 30,000 volunteers currently involved in United States in phase 3 trials.
- The trials are being conducted at over 80 sites at present in US.
- May be launched by end of 2020 or early 2021
Coronavirus vaccines by Pfizer and Moderna
- These are the two vaccines being developed in United States and are also under phase 3 late-stage clinical trials.
- Pfizer and its German partner BioNTech said they expect to have enough early-stage data from phase 3 study in October to submit an application to the FDA.
- Currently, the vaccine is being tested whether it is safe for elderly people.
- Pfizer said it will seek emergency use authorisation for the vaccine from the US Food and Drug Administration, once it was established that it is effective.
- Over 23,000 volunteers enrolled for stage-3 trials.
- May be launched in first quarter of 2021
- Over 30,000 healthy volunteers are enrolled in late-stage trials began in late-July, expected to be completed by September end.
China’s coronavirus vaccines
- China is also developing its own vaccines. Currently, work on over 5 vaccines is underway.
- The trials on various vaccine candidates are underway but none are in the activated stage.
- However, the government allowed emergency authorisation of the vaccine developed by Sinopharm with a section of its population getting the doses.
- Its late stage clinical trials are still underway.
Sputnik V | Russia's coronavirus vaccine
- Russia launched world's first coronavirus vaccine in August.
- Its very first doses were given to President Vladimir Putin’s daughter.
- Though WHO raised concerns, Russia said its vaccine is safe and has begun mass production already.
- Recently, study published in Lancet journal said Russia's vaccine has proved to be immunogenic generating an immune system response against SARS CoV-2 without any serious adverse effects in early stage trials.
- Russia is also in talks with the Indian government to manufacture its vaccine locally.
Covaxin | India’s indigenously developed coronavirus vaccine
- Covaxin is being developed by Hyderabad-based Bharat Biotech.
- It has received Centre's approval to begin phase 2 clinical trials.
- Phase 2 trials to be conducted on over 380 volunteers.
- Volunteers will be screened for 4 days after they are given vaccine shots.
- Covaxin’s Phase 3 human trials are expected to begin soon.
- May be launched by end of first-quarter of 2021 or start of second-quarter.
ALSO READ | Australia okays funding for 2 potential vaccines